Compass Therapeutics, Inc. (CMPX)
NASDAQ: CMPX · Real-Time Price · USD
2.920
-0.160 (-5.19%)
At close: Feb 21, 2025, 4:00 PM
3.000
+0.080 (2.74%)
After-hours: Feb 21, 2025, 5:59 PM EST
Compass Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Compass Therapeutics stock have an average target of 12.5, with a low estimate of 5.00 and a high estimate of 32. The average target predicts an increase of 328.08% from the current stock price of 2.92.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Compass Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 4 | 4 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Initiates $12 | Buy | Initiates | $12 | +310.96% | Feb 19, 2025 |
| Jefferies | Jefferies | Strong Buy Maintains $7 → $8 | Strong Buy | Maintains | $7 → $8 | +173.97% | Feb 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +242.47% | Jan 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +242.47% | Jan 8, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $32 | Strong Buy | Maintains | $32 | +995.89% | Jan 8, 2025 |
Financial Forecast
Revenue This Year
888.86K
Revenue Next Year
6.34M
from 888.86K
Increased by 613.39%
EPS This Year
-0.36
from -0.33
EPS Next Year
-0.40
from -0.36
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 945,000 | 26.3M | 129.6M | |||
| Avg | 888,859 | 6.3M | 48.3M | |||
| Low | 833,000 | n/a | 13.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 2,853.2% | 1,944.3% | |||
| Avg | - | 613.4% | 662.2% | |||
| Low | - | - | 112.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.34 | -0.20 | 0.33 | |||
| Avg | -0.36 | -0.40 | -0.44 | |||
| Low | -0.38 | -0.67 | -1.16 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.